NCT05745701已完成1 期
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine
研究概览
简要总结
This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants.
The 3 study periods will be conducted consecutively without a break.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Otherwise healthy female and male participants must be at least 18 years of age at the time of signing the ICD (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, physical examination, including blood pressure and pulse rate measurement, standard 12-lead ECG and clinical laboratory tests).
- •BMI: ≥25.0 kg/m2 at Screening.
- •Stable body weight, defined as <5 kg change (per participant report) for 90 days before Screening.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at Screening.
- •Any malignancy not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin)
- •Personal or family history of MTC or MEN2, or study participants with suspected MTC per the investigator's judgment.
- •Acute pancreatitis, a history of repeated episodes of acute pancreatitis, or history of chronic pancreatitis.
- •Symptomatic gallbladder disease.
- •Medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders (eg, Cushing Syndrome).
- •History of depressive disorder or history of other severe psychiatric disorders (eg, schizophrenia or bipolar disorder) within the last 2 years from screening.
- •Known medical history of active liver disease, including chronic hepatitis B or C, primary biliary cirrhosis, alcoholic liver disease, primary sclerosing cholangitis, autoimmune hepatitis, overlap syndrome, or prior known drug-induced liver injury.
- •History of HIV infection.
- •Any lifetime history of a suicide attempt.
- •Use of prohibited medications
- •Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
- •Standard 12-lead ECG that demonstrates clinically relevant abnormalities that mayaffect participant safety or interpretation of study result.
- •Participants with clinical laboratory test abnormalities at Screening. -
研究组 & 干预措施
Period 1: PF-07081532
Active Comparator
Participants will receive PF-07081532 as a single dose on Day 1.
干预措施: PF-07081532 (Drug)
Period 2: Cyclosporine + PF-07081532
Experimental
Participants will receive a single dose of PF-07081532 and a single dose of cyclosporine on Day 1.
干预措施: PF-07081532 (Drug)
Period 2: Cyclosporine + PF-07081532
Experimental
Participants will receive a single dose of PF-07081532 and a single dose of cyclosporine on Day 1.
干预措施: Cyclosporine (Device)
Period 3: Itraconazole + PF-07081532
Experimental
Participants will receive itraconazole daily for 9 days plus a single dose of PF-07081532 on Day 4.
干预措施: PF-07081532 (Drug)
Period 3: Itraconazole + PF-07081532
Experimental
Participants will receive itraconazole daily for 9 days plus a single dose of PF-07081532 on Day 4.
干预措施: Itraconazole (Drug)
结局指标
主要结局
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine
时间窗: Pre-dose of lotiglipron and at 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, and 144 (for Period 3 only) hours post dose of lotiglipron on Day 1 of Periods 1 and 2 and on Day 4 of Period 3.
AUCinf is area under the plasma concentration-time profile from time zero extrapolated to infinite time. AUCinf is caluculated by AUClast + (Clast/kel), where Clast is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis.
次要结局
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)(From the first dose up to 35 days after administration of the final dose of study intervention (Period 3 Day 9, Study Day 19), the maximum duration was 54 Days)
- Number of Participants With Laboratory Abnormalities(Baseline (pre-dose on Day 1), Period 2 Day 5 (Study Day 10), and Period 3 Day 10 (Study Day 20))
- Number of Participants Meeting Pre-Specified Criteria of Vital Signs(Pre-dose Day 1 in periods 1, 2 and 3 (Study Days 1, 6, and 11, respectively), and prior to discharge on Period 3 Day 10 (Study Day 20))
- Change From Baseline in Body Weight at the End of Periods 1, 2, and 3(Baseline (pre-dose on Day 1), Day 5 of Period 1 (Study Day 5), Day 5 of Period 2 (Study Day 10), and Day 10 of Period 3 (Study Day 20))
- Number of Participants Meeting Pre-Specified Criteria of Electrocardiogram (ECGs)(Pre-dose Day 1 in periods 1, 2 and 3 (Study Days 1, 6, and 11, respectively), and prior to discharge on Period 3 Day 10 (Study Day 20))
- Number of Participants With Suicidal Ideation or Behavior According to Columbia Suicide Severity Rating Scale (C-SSRS)(Period 1 Day -1 (Study Day -1), Period 3 Day 10 (Study Day 20) or Early Termination visit)
- Number of Participants With a Score of ≥15 on Patient Health Questionnaire-9 (PHQ-9)(Period 1 Day -1 (Study Day -1), Period 3 Day 10 (Study Day 20) or Early Termination visit)
- Maximum Observed Plasma Concentration (Cmax) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine(Pre-dose of lotiglipron and at 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, and 144 (for Period 3 only) hours post dose of lotiglipron on Day 1 of Periods 1 and 2 and on Day 4 of Period 3.)
- Time to Cmax (Tmax) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine(Pre-dose of lotiglipron and at 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, and 144 (for Period 3 only) hours post dose of lotiglipron on Day 1 of Periods 1 and 2 and on Day 4 of Period 3.)
- Apparent Oral Clearance (CL/F) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine(Pre-dose of lotiglipron and at 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, and 144 (for Period 3 only) hours post dose of lotiglipron on Day 1 of Periods 1 and 2 and on Day 4 of Period 3.)
- Apparent Oral Volume of Distribution (Vz/F) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine(Pre-dose of lotiglipron and at 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, and 144 (for Period 3 only) hours post dose of lotiglipron on Day 1 of Periods 1 and 2 and on Day 4 of Period 3.)
- Terminal Half-life (t1/2) of Lotiglipron When Administered Alone and With Itraconazole or Cyclosporine(Pre-dose of lotiglipron and at 0.5, 1, 2, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, and 144 (for Period 3 only) hours post dose of lotiglipron on Day 1 of Periods 1 and 2 and on Day 4 of Period 3.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyMalignant Melanoma, NeoplasmsNCT01851824Hoffmann-La Roche9
已完成
1 期
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic MalignanciesMalignant Melanoma, NeoplasmsNCT01844674Hoffmann-La Roche18
已完成
1 期
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)HIV InfectionsNCT04630002ViiV Healthcare54
已完成
1 期
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy ParticipantsHealthy ParticipantsNCT05067439Pfizer26
已完成
1 期
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of VadadustatDrug Interaction PotentiationPharmacokineticsNCT03789032Akebia Therapeutics20